Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
June 10 2021 - 04:30PM
Business Wire
- Annual Meeting to be adjourned solely with respect to Proposal
2 (Increase in Authorized Shares of Common Stock)
- Both Leading Independent Advisory Firms Have Issued Favorable
Recommendations on Proposal 2
Clovis Oncology, Inc. (NASDAQ:CLVS) (the “Company”) today
announced partial results and the partial adjournment of its 2021
Annual Meeting of Stockholders (the “Annual Meeting”). The Company
adjourned the Annual Meeting solely with respect to Proposal 2 set
forth in its Definitive Proxy Statement filed with the Securities
and Exchange Commission on April 28, 2021 (as supplemented, “Proxy
Statement”). Proposal 2 is a proposal to amend the Company’s
Amended and Restated Certificate of Incorporation, as amended, to
increase the number of shares of common stock the Company is
authorized to issue from 200 million shares to 250 million shares.
The Company has adjourned the Annual Meeting solely with respect to
Proposal 2 to provide its stockholders additional time to vote on
Proposal 2. The Annual Meeting will resume with respect to Proposal
2 at 8:30 a.m. Mountain Time on June 23, 2021 and will continue to
be held at the St. Julien Hotel, 900 Walnut Street, Boulder,
Colorado 80302.
The Company also announced, that at the Annual Meeting, all
director nominees were elected and Proposals 3, 4, 5 and 6 were
approved by the Company’s stockholders.
Support for Proposal 2 has exceeded 67.8% of the votes cast on
the proposal. However, the affirmative vote of holders of more than
50% of all of the Company’s issued and outstanding shares of common
stock is necessary for Proposal 2 to be approved.
The record date for determining stockholders eligible to vote at
the Annual Meeting will remain the close of business on April 12,
2021. Stockholders who have already submitted a proxy do not need
to vote again for the reconvened Annual Meeting, as the proxies
submitted will remain valid. Stockholders who have already
submitted proxies and want to change their vote with respect to
Proposal 2 can update their vote in the manner set forth in the
Proxy Statement. Your vote will be recorded at the Annual Meeting
in accordance with your most recently submitted proxy.
Stockholders as of close of business on the April 12, 2021
record date who have not voted are encouraged to vote. Stockholders
needing assistance voting or have questions may contact the firm
assisting the Company with the solicitation of proxies, Innisfree
M&A Incorporated, toll-free at +1 (877) 456-3524.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer
agents in the U.S., Europe and additional international markets.
Clovis Oncology targets development programs at specific subsets of
cancer populations, and simultaneously develops, with partners, for
those indications that require them, diagnostic tools intended to
direct a compound in development to the population that is most
likely to benefit from its use. Clovis Oncology is headquartered in
Boulder, Colorado with additional office locations in the U.S. and
Europe.
Additional Information and Where to Find It
The Company has filed a definitive Proxy Statement with the U.S.
Securities and Exchange Commission (the “SEC”), which was filed on
April 28, 2021 as supplemented on May 28, 2021. The Company, its
directors, its executive officers and certain other individuals set
forth in the Proxy Statement, as supplemented, will be deemed
participants in the solicitation of proxies from stockholders in
respect of the Annual Meeting. Information regarding the names of
the Company’s directors and executive officers and certain other
individuals and their respective interests in the Company by
security holdings or otherwise is set forth in the Proxy Statement.
BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE
URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE
SEC, INCLUDING THE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO AND
ACCOMPANYING PROXY CARD. Investors and stockholders may obtain
copies of all documents filed by the Company with the SEC,
including the Proxy Statement, free of charge at the SEC’s website,
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210610005794/en/
Anna Sussman 303.625.5022 asussman@clovisoncology.com
Breanna Burkart 303.625.5023 bburkart@clovisoncology.com
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Mar 2023 to Mar 2024